Intestinal Infusion Gel Helps Ease Symptoms in Advanced Parkinson’s

A new study from Romania brings encouraging news for people with advanced Parkinson’s disease. The researchers found that delivering medication through a tiny tube directly into the intestines significantly improved both movement and non-motor symptoms in severely affected people. Why This Matters As Parkinson’s progresses, oral medications like levodopa often stop working well. The body’s digestive system may slow down or become less effective at absorbing medication—making symptom control harder. For people who already take multiple daily doses and still experience “off” periods (when medication effects wear off), freezing, dyskinesia (involuntary movements), or sudden loss of movement, a device-assisted approach can offer much-needed relief. What the Study Did This was a single-site study with 20 people who had advanced Parkinson’s. Researchers implanted a small tube (known as PEG-J) through which an intestinal gel containing levodopa, carbidopa, and entacapone was infused directly into the intestines. People were assessed at three points: before implantation, right after, and six months later. Big Improvements on Key Symptoms Motor Symptoms: “On” time—the hours when medication is actively helping—jumped from about 5 hours a day to over 12 hours. “Off” time plummeted from nearly 10 hours to less than 2 hours. Freezing episodes dropped sharply from around 4.4 hours daily to less than one hour. Fewer dyskinesia episodes and less morning stiffness (akinesia) were reported. Non-Motor Symptoms: People also experienced fewer symptoms of depression and sleep problems. Many were able to reduce their doses of antidepressant and antipsychotic medications. Cognitive function remained stable. Quality of Life: People and their families reported noticeable improvements in daily life. Many regained independence—managing home tasks, finances, even traveling again. Safety & Side Effects Most people tolerated the treatment well. While many experienced mild pneumoperitoneum (air under the diaphragm) after the procedure, it didn’t require additional treatment. One person had a blood clot and was treated accordingly, leading to a change in hospital protocol—now, a short course of blood thinner is given after the tube is placed. Two people dropped out: one due to cancer, another due to a severe stoma infection. What Are the Limitations? Small study group and only one location. Short follow-up—six months is helpful but doesn’t show long-term effects. Findings may not be generalisable to wider Parkinson’s populations without further testing. The Bottom Line The intestinal gel infusion offers a promising alternative for people whose oral medications are no longer effective. It delivers more steady medication levels, significantly improving movement, mood, and sleep—and boosting quality of life too. While more research is needed to confirm longer-term safety and effectiveness, this study adds valuable real-world data supporting this innovative approach to advancing Parkinson’s care.